Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

rapie versus der Placebobehandlung zusätzlich zur Standardtherapie bei Patienten mit Diabetes Typ 2 und einem erst kurz vorher aufgetretenen akuten Koronarsyndrom (innerhalb von 15 bis 90 Tagen vor der Randomisierung). Die Studie hatte als primären kombinierten Endpunkt kardiovaskulären Tod, nicht tödlichen Herzinfarkt und nicht tödlichen Schlaganfall.

In der Alogliptin-Gruppe erhielten 71,4 % der Patienten 25 mg, 25,7 % 12,5 mg und 2,9 % 6,25 mg täglich. Die Alogliptin-Dosierungen wurden entsprechend der Nierenfunktion angepasst: geschätzte glomeruläre Filtrationsrate (gGFR) durch die MDRD-Formel (Modification in Diet in Renal Disease) > 60 ml/min, 25 mg täglich; < 60 ml/min und  > 30 ml/min, 12,5 mg täglich; und < 30 ml/min, 6,25 mg täglich. Das Studienpräparat wurde in beiden Gruppen ähnlich häufig vorzeitig abgesetzt. (20,9 % bzw. 22,6 % der Patienten). Die mittlere Expositionsdauer betrug 533 Tage (Quartilsabstand 280 bis 751 Tage). Zum Ende der Studie betrug die mittlere Veränderung des HbA1c versus dem Ausgangspunkt 0,33% bzw. 0,03% in der Alogliptin- und der Placebogruppe, und der Mittelwert der Differenz der HbA1c-Werte zwischen Alogliptin und Placebo betrug -0,36% (95 % KI, -0,43, -0.28, p<0,001). Die Ergebnisse der einzelnen Komponenten des primären Endpunktes stimmten mit dessen Gesamtauswertung überein. Dies traf auch für die Gesamtmortalität und den kardiovaskulären Tod zu. Die Unterschiede waren jeweils nicht signifikant.

Takeda führte die globale EXAMINE-Studie gemäß den Leitlinien der US-amerikanischen Food and Drug Administration (FDA) von 2008 („Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes) durch. Die EXAMINE-Ergebnisse werden nach Abschluss aller Analysen ordnung
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons ... the key link between the medical device industry and ... more in the coming years as the device industry ... According to research by benchmarking firm, Best Practices, ... gain an important edge is by harnessing new technology ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... Like many other diagnostic regimes that were previously ... entering the clinical mainstream. Smaller, simpler analyzer systems ... large physicians group labs, while some genetic test ... care locations such as clinics and physician offices., ...
... to plan or evaluate anticoagulant therapy, to ... elevated factor VIII levels, dysfibrinogenemia, factor XII ... to assess acquired conditions, such as pregnancy, ... Prothrombin levels are also monitored along with ...
Cached Medicine Technology:Genetic Analysis Systems Enter the Clinical Mainstream 2Genetic Analysis Systems Enter the Clinical Mainstream 3Prothrombin Time Comes in Small (CLIA-Waived) Packages 2Prothrombin Time Comes in Small (CLIA-Waived) Packages 3
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2
... being male did have a correlation , , FRIDAY, March ... extent of head flattening in infants, U.S. researchers say. ... asymmetrical head shape, known as deformational plagiocephaly (DP), in ... Since the early 1990s, parents have been encouraged to ...
... stents were safe and superior to bare metal stents ... patients enrolled in a nationwide registry of cardiovascular disease, ... , The findings were presented today at the i2Summit ... Session. They also appear online in the Journal ...
... Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") ... ended December 31, 2008. For the three months ended December ... from revenues of $389,000 in the prior year period, and ... compared with net income of $38,000 ($0.01 per share) for ...
... March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) ... company announced the clinical trial protocol for their MMR ... approved by the end of the second quarter 2009. ... live attenuated viruses administered via injection for immunization against ...
... and Social Responsibility Targets to be met by ... Gamble Company (NYSE: PG ) today ... goals. The updates reflect the company,s continued ... of P&G,s products and operations and bettering lives ...
... of the Simulated Impaired Driving Experience(R), (SIDNE(R)), will be ... the Lifesavers conference at the Gaylord Opryland Resort and ... 31. The Lifesavers Conference is a national traffic safety ... our nation,s roadways. "We are excited to demonstrate our ...
Cached Medicine News:Health News:Baby's Sleep Position May Not Affect Severity of Head Flattening 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 2Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 3Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 4Health News:Human Pheromone Sciences Announces Fourth Quarter and Full Year Results 5Health News:Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 2Health News:Procter & Gamble Deepens Corporate Commitment to Sustainability 3Health News:Innocorp, ltd. to Attend Lifesavers Conference 2
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
This blanket is ideal for warming the large child or small adult during upper body surgery....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: